More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes
The STEP 4 trial, which specifically examined semaglutide withdrawal, showed that participants who stopped the medication regained 6.9% of body weight over 48 weeks, while those who continued treatment lost an additional 7.9%
The reduced appetite that comes along with taking a GLP-1 can make your food choices all the more important
For more information, visit medevidence.com, encoredocs.com or read more about ongoing obesity trials at this link here.
"Novo Nordisk A/S Insider Trading & Ownership Structure"
Seek clinics dedicated to providing ongoing support beyond the prescription